• Travere posted Q2 GAAP net loss of USD 34.8 million, or USD 0.37 per share, versus a loss of USD 12.8 million a year earlier.
• Net sales rose 70.15% year over year to USD 161.4 million, driven by FILSPARI net sales up 96% to USD 141.1 million.
• R&D expense increased 22.06% to USD 60.3 million; SG&A climbed 53.54% to USD 96.1 million.
• Other expense widened to USD 39 million on a USD 40 million inducement expense tied to 2029 convertible note repurchases.
• Received 2,012 new patient start forms in the quarter; closed civorebrutinib in-licensing in July; pegtibatinase Phase 3 HARMONY topline data expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608041601BIZWIRE_USPR_____20260804_BW067885) on August 04, 2026, and is solely responsible for the information contained therein.